Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse.
Katja SockelFriedrich StölzelFranziska HönlHenning BaldaufChristoph RölligMartin WermkeMalte von BoninRaphael TeipelCornelia Link-RachnerKalina BrandtFrank KroschinskyMathias HänelAnke MorgnerChristian KlesseGerhard EhningerUwe PlatzbeckerMartin BornhäuserJohannes ScheteligJan Moritz MiddekePublished in: Cancer management and research (2022)
Allogeneic HCT in aplasia with a melphalan-based conditioning regimen has the potential to cure a subset of adverse risk AML patients, even with persistent morphological disease prior HCT. However, a high pre-transplant blast count still indicates patients with a dismal prognosis, especially in the relapsed patient group, for whom post-transplant strategies should be considered to further optimize post HCT outcome.
Keyphrases
- stem cell transplantation
- high dose
- acute myeloid leukemia
- low dose
- end stage renal disease
- ejection fraction
- newly diagnosed
- cell cycle arrest
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- diffuse large b cell lymphoma
- peripheral blood
- multiple myeloma
- risk assessment
- cell proliferation
- human health